Fujirebio | GenomeWeb

Fujirebio

Affymetrix has been awarded

A longitudinal study of the Risk of Ovarian Cancer Algorithm has found that the algorithm in combination with transvaginal ultrasound offers suitable specificity and positive predictive value for it to be used as an ovarian cancer screening test in post-menopausal women.

This article has been updated from a version posted Oct. 12 to include additional information.

Australian diagnostics firm Healthlinx has reached an agreement to sell the majority of its intellectual property along with existing commercial and distribution agreements to newly formed San Diego-based diagnostics company Mane Cancer Diagnostics.

According to data presented this week at the European Society of Gynecological Oncology meeting in Milan, Vermillion's OVA1 ovarian cancer diagnostic achieved 98.1 percent sensitivity when used in conjunction with imaging.

This story originally ran on Sept. 6 and has been updated to include comments from a competing firm.
By Adam Bonislawski

The quarter's OVA1 sales numbers exceeded Vermillion's guidance of between 3,200 and 3,500 tests and the company predicted that sales would continue to accelerate, offering a guidance of between 4,000 and 4,300 tests for Q3. Concerns about costs and potential competitors loom, however.

By combining HE4 with CA125 detection capabilities in a single test, Abbott is hoping to improve doctors' ability to identify women at risk for ovarian cancer.

BD and Fujirebio will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.